RxDoctor Payments Data

Daniel Franco, MD

Internal Medicine · Dunedin, FLNPI 1346289469

Payments from drug & device makers

$662in general payments, 2019–2025

Across 20 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$187
  • Abbott$115
  • AbbVie$84
  • Pfizer$78
  • Sanofi Pasteur Inc.$68
  • Merck$40
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$662100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker2$187
Abbott1$115
AbbVie(2 entities)3$84
Pfizer5$78
Sanofi Pasteur Inc.3$68
Merck2$40
GSK2$38
Sanofi-aventis U.S. LLC1$32
Exact Sciences1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$167,140
Medicare patients
423
Services billed
1,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate72$85,314
JardianceEmpagliflozin67$79,440
MounjaroTirzepatide63$65,637
OzempicSemaglutide51$62,027
EliquisApixaban64$59,265
XareltoRivaroxaban49$43,015
TrulicityDulaglutide32$40,802
JanumetSitagliptin Phos/Metformin Hcl31$25,685
FarxigaDapagliflozin Propanediol16$25,057
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,205
Advair HfaFluticasone Propion/Salmeterol31$11,381
CreonLipase/Protease/Amylase12$9,709
LinzessLinaclotide18$9,516
Atorvastatin Calcium716$6,001
SymbicortBudesonide/Formoterol Fumarate21$5,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$40$110,999103 claims
PfizerEliquis$78$59,26564 claims
AbbVieCreon, Linzess, Synthroid$84$24,03886 claims
GSKTrelegy Ellipta$38$12,20519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Dunedin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →